Cell and gene therapy at the heart of healthcare innovation

6 May 2022

An Expert View from Mark Brewer, research director, Life Sciences, finnCap.

Heralding an encouraging new era of innovative technologies within the life sciences sector with long-term benefits and curative potential, cell and gene therapy (CGT) has been seen as the ‘future’ of medicine for many years.

We are closer than ever to that future becoming the present. The year 2021 was one of highs and lows - the year was historical in terms of fundraising, driven by increasing VC interest in addition to public market appetite for the sector. We expect to see the strong M&A activity of 2021 continuing into 2022 and beyond, as large pharma continues to bolster its access to CGT technology, manufacturing, and product pipelines. We see more and more CGT therapies and technologies coming of age, as the sector navigates challenges such as safety and tolerability, manufacturing, reimbursement, and the regulatory framework against the backdrop of the best year on record for potential approvals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK